Loading
A phase 2 trial of Midostaurin, Fludarabine, Cytarabine, Daunorubicin, Idarubicin and Mitoxantrone in acute myeloid leukaemia, run by Novartis Pharmaceuticals, active and no longer recruiting.
A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML is a phase 2 interventional study registered as NCT03591510 by Novartis Pharmaceuticals, with 22 participants enrolled, started 2019-03-13 and due to reach its primary completion in 2029-05-18. Interventions recorded: Midostaurin, Fludarabine, Cytarabine, Daunorubicin or idarubicin, Mitoxantrone and Etoposide.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Idarubicin, Daunorubicin, Cytarabine, Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia in children, Fludarabine, Cytarabine, Acute myeloid leukaemia and the tag pipeline.
Shares Mitoxantrone, Fludarabine, Cytarabine, Acute myeloid leukaemia and the tag pipeline.
Shares Mitoxantrone, Daunorubicin, Acute myeloid leukaemia and the tag pipeline.
Shares Idarubicin, Mitoxantrone, Daunorubicin, Cytarabine and the tag pipeline.
Shares Daunorubicin, Cytarabine, Novartis and the tag pipeline.
Shares Idarubicin, Mitoxantrone, Cytarabine and the tag pipeline.
Shares Mitoxantrone, Daunorubicin, Cytarabine, Acute myeloid leukaemia and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/